Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578 and Nivolumab with Chemo in Metastatic Pancreatic Cancer
NCT06538207Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-4578 (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 28 days and Adverse event. Started Jan 2021; status: completed.
02
Drugs
ONO-4578
Beyond the preview
Go deeper on NCT06538207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538207.